Clinical Trials Logo

Clinical Trial Summary

Based on the need of clinical practice of maintenance therapy for advanced NSCLC and the reliable data of third-line treatment for non-small cell lung cancer, the investigators designed a clinical study of antinil hydrochloride versus pemetrexed in maintenance therapy for advanced NSCLC to prospectively evaluate the efficacy of antinil hydrochloride in maintenance therapy for advanced NSCLC. Value, to provide a scientific basis for prolonging the survival time of patients with advanced NSCLC, improving the quality of life of patients in the course of treatment, and optimizing treatment strategies to a greater extent.


Clinical Trial Description

This study is planned to be carried out in Jiangsu regional multi-center. 83 cases are preliminarily expected to be included. The study started in December 2018 and ended in December 2019. It is expected that the trial will end in December 2020.

In the absence of such situations as withdrawal of informed consent, intolerance of drug toxicity and side effects, or inappropriateness for further trials, each participant's expected time for research and treatment will continue until radiographically confirmed tumor progression occurs. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03769805
Study type Interventional
Source The First Affiliated Hospital with Nanjing Medical University
Contact Yongqian Shu, PhD
Phone 00862568306428
Email shuyongqian@csco.org.cn
Status Recruiting
Phase N/A
Start date June 15, 2019
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT06147570 - A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Phase 2
Recruiting NCT01312337 - Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT05860582 - A Study of [14C]GB491 in Male Healthy Subjects Phase 1
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT02562027 - SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer N/A
Recruiting NCT05358249 - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2
Active, not recruiting NCT02954523 - Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Phase 1/Phase 2
Terminated NCT03998189 - Metabolic and Microbial Profiling of Lung Cancer N/A
Not yet recruiting NCT03258671 - IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer N/A
Recruiting NCT03838588 - The Tracking Molecular Evolution for NSCLC (T-MENC) Study
Active, not recruiting NCT04984811 - NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Phase 2
Recruiting NCT05688280 - Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS Phase 1/Phase 2
Recruiting NCT02974933 - Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Phase 2
Recruiting NCT02951611 - Effects of Acupuncture Stimulation on Systemic Inflammation N/A
Active, not recruiting NCT02980536 - cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China
Completed NCT02972216 - Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Phase 4
Recruiting NCT02905591 - A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC Phase 2
Recruiting NCT05873439 - Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC Early Phase 1
Active, not recruiting NCT02981108 - A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC Phase 1/Phase 2
Active, not recruiting NCT02299141 - Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Phase 2